Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.

Svensson RJ, Niward K, Davies Forsman L, Bruchfeld J, Paues J, Eliasson E, Schön T, Simonsson USH.

Br J Clin Pharmacol. 2019 Jul 3. doi: 10.1111/bcp.14048. [Epub ahead of print]

PMID:
31269277
2.

Efficacy of Mentalization-based group therapy for adolescents: the results of a pilot randomised controlled trial.

Griffiths H, Duffy F, Duffy L, Brown S, Hockaday H, Eliasson E, Graham J, Smith J, Thomson A, Schwannauer M.

BMC Psychiatry. 2019 Jun 6;19(1):167. doi: 10.1186/s12888-019-2158-8.

3.

Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.

Kurland S, Furebring M, Löwdin E, Eliasson E, Nielsen EI, Sjölin J.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02466-18. doi: 10.1128/AAC.02466-18. Print 2019 Jun.

PMID:
30962329
4.
5.

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.

Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J.

BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899.

6.

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.

Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, Carlsson B, Pohanka A, Mansjö M, Jonsson Nordvall M, Johansson AG, Eliasson E, Werngren J, Paues J, Simonsson USH, Schön T.

J Antimicrob Chemother. 2018 Oct 1;73(10):2838-2845. doi: 10.1093/jac/dky268.

PMID:
30124844
7.

Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.

Niward K, Ek Blom L, Davies Forsman L, Bruchfeld J, Eliasson E, Schön T, Chryssanthou E, Paues J.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00218-18. doi: 10.1128/AAC.00218-18. Print 2018 May.

8.

Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study.

Smith RL, Haslemo T, Andreassen OA, Eliasson E, Dahl ML, Spigset O, Molden E.

CNS Drugs. 2017 Nov;31(11):991-997. doi: 10.1007/s40263-017-0469-1.

PMID:
28948574
9.

Reply to 'Multiple and Opposite Effects of Angiotensin II Receptor Blockers on the Bioavailability of Epoxyeicosatrienoic Acids'.

Senda A, Mukai Y, Hayakawa T, Kato Y, Eliasson E, Rane A, Toda T, Inotsume N.

Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):215-216. doi: 10.1111/bcpt.12811. Epub 2017 Jun 22. No abstract available.

10.

Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.

Senda A, Mukai Y, Hayakawa T, Kato Y, Eliasson E, Rane A, Toda T, Inotsume N.

Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):239-245. doi: 10.1111/bcpt.12789. Epub 2017 May 10.

11.

Potassium-Channel-Independent Relaxing Influence of Adipose Tissue on Mouse Carotid Artery.

Laskowski M, Andersson C, Eliasson E, Golubinskaya V, Nilsson H.

J Vasc Res. 2017;54(1):51-57. doi: 10.1159/000458421. Epub 2017 Mar 24.

PMID:
28334715
12.

Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.

Petersson J, Giske CG, Eliasson E.

Acta Anaesthesiol Scand. 2016 Nov;60(10):1425-1436. doi: 10.1111/aas.12808. Epub 2016 Sep 21.

PMID:
27655029
13.

Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8.

Senda A, Mukai Y, Toda T, Hayakawa T, Yamashita M, Eliasson E, Rane A, Inotsume N.

Biol Pharm Bull. 2015;38(12):1975-9. doi: 10.1248/bpb.b15-00577.

14.

The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.

Mukai Y, Senda A, Toda T, Eliasson E, Rane A, Inotsume N.

Basic Clin Pharmacol Toxicol. 2016 Jun;118(6):408-14. doi: 10.1111/bcpt.12520. Epub 2015 Dec 28.

15.

Simultaneous Determination Method of Epoxyeicosatrienoic Acids and Dihydroxyeicosatrienoic Acids by LC-MS/MS System.

Mukai Y, Toda T, Takeuchi S, Senda A, Yamashita M, Eliasson E, Rane A, Inotsume N.

Biol Pharm Bull. 2015;38(10):1673-9. doi: 10.1248/bpb.b15-00480.

16.

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.

Mannheimer B, Haslemo T, Lindh JD, Eliasson E, Molden E.

Ther Drug Monit. 2016 Feb;38(1):127-34. doi: 10.1097/FTD.0000000000000251.

PMID:
26418700
17.

Effect of aging on brain injury prediction in rotational head trauma--a parameter study with a rat finite element model.

Antona-Makoshi J, Eliasson E, Davidsson J, Ejima S, Ono K.

Traffic Inj Prev. 2015;16 Suppl 1:S91-9. doi: 10.1080/15389588.2015.1021416.

PMID:
26027980
18.

Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex.

Hatta FH, Lundblad M, Ramsjo M, Kang JH, Roh HK, Bertilsson L, Eliasson E, Aklillu E.

OMICS. 2015 Jun;19(6):346-53. doi: 10.1089/omi.2015.0022. Epub 2015 May 15.

PMID:
25977991
19.

[Few drugs dominate among clinically important interactions. Swedish register study lists problem drugs].

Holm J, Eiermann B, Eliasson E, Mannheimer B.

Lakartidningen. 2015 Mar 30;112. pii: DEDP. Swedish.

20.
21.

[The medical students association protests against new lending rules: Should education abroad become a class issue?].

Forssén M, Eliasson E.

Lakartidningen. 2015 Mar 11;112. pii: DEFE. Swedish. No abstract available.

22.

Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.

Mukai Y, Senda A, Toda T, Hayakawa T, Eliasson E, Rane A, Inotsume N.

Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):493-8. doi: 10.1111/bcpt.12355. Epub 2014 Dec 23.

23.

[Renal transplantation in patients with lupus nephritis].

Katalinić L, Eliasson E, Bubić-Filipi L, Kes P, Anić B, Basić-Jukić N.

Lijec Vjesn. 2014 Jul-Aug;136(7-8):219-23. Review. Croatian.

PMID:
25327010
24.

A limited number of prescribed drugs account for the great majority of drug-drug interactions.

Holm J, Eiermann B, Eliasson E, Mannheimer B.

Eur J Clin Pharmacol. 2014 Nov;70(11):1375-83. doi: 10.1007/s00228-014-1745-3. Epub 2014 Sep 6.

PMID:
25190295
25.

Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro.

Mukai Y, Toda T, Hayakawa T, Eliasson E, Rane A, Inotsume N.

Biol Pharm Bull. 2014;37(9):1550-4.

26.

A method to model anticipatory postural control in driver braking events.

Östh J, Eliasson E, Happee R, Brolin K.

Gait Posture. 2014 Sep;40(4):664-9. doi: 10.1016/j.gaitpost.2014.07.021. Epub 2014 Aug 1.

27.

Posaconazole concentrations in human tissues after allogeneic stem cell transplantation.

Blennow O, Eliasson E, Pettersson T, Pohanka A, Szakos A, El-Serafi I, Hassan M, Ringdén O, Mattsson J.

Antimicrob Agents Chemother. 2014 Aug;58(8):4941-3. doi: 10.1128/AAC.03252-14. Epub 2014 Jun 2.

28.

Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives.

Nylén H, Björkhem-Bergman L, Ekström L, Roh HK, Bertilsson L, Eliasson E, Lindh JD, Diczfalusy U.

Basic Clin Pharmacol Toxicol. 2014 Oct;115(4):366-71. doi: 10.1111/bcpt.12230. Epub 2014 Apr 11.

29.

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.

Mannheimer B, Holm J, Koukel L, Bertilsson L, Osby U, Eliasson E.

Eur J Clin Pharmacol. 2014 Jun;70(6):695-9. doi: 10.1007/s00228-014-1664-3. Epub 2014 Mar 20.

PMID:
24643635
30.

Therapeutic drug monitoring for tomorrow.

Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl ML.

Eur J Clin Pharmacol. 2013 May;69 Suppl 1:25-32. doi: 10.1007/s00228-013-1504-x. Epub 2013 May 3. Review.

PMID:
23640185
31.

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.

Margolin S, Lindh JD, Thorén L, Xie H, Koukel L, Dahl ML, Eliasson E.

Pharmacogenomics. 2013 Apr;14(6):613-22. doi: 10.2217/pgs.13.47.

PMID:
23570465
32.

Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study.

Björkhem-Bergman L, Nylén H, Norlin AC, Lindh JD, Ekström L, Eliasson E, Bergman P, Diczfalusy U.

Drug Metab Dispos. 2013 Apr;41(4):704-8. doi: 10.1124/dmd.113.051136. Epub 2013 Feb 5.

PMID:
23386704
33.

Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA).

Hanberger H, Edlund C, Furebring M, G Giske C, Melhus A, Nilsson LE, Petersson J, Sjölin J, Ternhag A, Werner M, Eliasson E; Swedish Reference Group for Antibiotics.

Scand J Infect Dis. 2013 Mar;45(3):161-75. doi: 10.3109/00365548.2012.747694. Epub 2012 Dec 28. Review.

PMID:
23270477
34.

Institutional profile: Karolinska Institutet.

Eliasson E, Sim SC, Rane A, Ingelman-Sundberg M.

Pharmacogenomics. 2012 Dec;13(16):1887-91. doi: 10.2217/pgs.12.176.

PMID:
23215881
35.

Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.

Skogastierna C, Björkhem-Bergman L, Bergman P, Eliasson E, Rane A, Ekström L.

J Cardiovasc Pharmacol. 2013 Jan;61(1):1-7. doi: 10.1097/FJC.0b013e3182734508.

PMID:
22987053
36.

Vitamin D and drug-metabolising enzymes.

Lindh JD, Björkhem-Bergman L, Eliasson E.

Photochem Photobiol Sci. 2012 Dec;11(12):1797-801. doi: 10.1039/c2pp25194a.

PMID:
22903070
37.

UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.

Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, Molden E, Eliasson E.

Clin Pharmacol Ther. 2012 Aug;92(2):221-7. doi: 10.1038/clpt.2012.46. Epub 2012 Jun 20.

PMID:
22713701
38.

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele.

Andersson ML, Eliasson E, Lindh JD.

Pharmacogenomics. 2012 May;13(7):757-62. doi: 10.2217/pgs.12.40.

PMID:
22594507
39.

Seasonal variation in blood drug concentrations and a potential relationship to vitamin D.

Lindh JD, Andersson ML, Eliasson E, Björkhem-Bergman L.

Drug Metab Dispos. 2011 May;39(5):933-7. doi: 10.1124/dmd.111.038125. Epub 2011 Feb 24.

PMID:
21349923
40.

Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide.

Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, Ekström L.

Heart Vessels. 2011 Nov;26(6):628-36. doi: 10.1007/s00380-010-0097-x. Epub 2011 Jan 7.

PMID:
21213109
41.

Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice.

Mannheimer B, Eliasson E.

J Intern Med. 2010 Dec;268(6):540-8. doi: 10.1111/j.1365-2796.2010.02303.x. Review.

42.

Clinically significant CYP2C inhibition by noscapine but not by glucosamine.

Rosenborg S, Stenberg M, Otto S, Ostervall J, Masquelier M, Yue QY, Bertilsson L, Eliasson E.

Clin Pharmacol Ther. 2010 Sep;88(3):343-6. doi: 10.1038/clpt.2010.107. Epub 2010 Jul 28.

PMID:
20668444
43.

["Silent" interactions are often missed. Different combinations of pharmaceuticals can result in non-drug effect].

Mannheimer B, Eliasson E.

Lakartidningen. 2010 Jun 2-8;107(22):1459. Swedish. No abstract available.

PMID:
20645594
44.

Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions.

Mannheimer B, Wettermark B, Lundberg M, Pettersson H, von Bahr C, Eliasson E.

Br J Clin Pharmacol. 2010 Apr;69(4):411-7. doi: 10.1111/j.1365-2125.2009.03598.x.

45.

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.

Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, Osby U.

Eur J Clin Pharmacol. 2010 May;66(5):465-74. doi: 10.1007/s00228-009-0783-8. Epub 2010 Feb 9.

PMID:
20143052
46.

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.

Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, Eliasson E, Fyhrquist F, Hille DA, Ibsen H, Lyle PA, Berg K, Sandberg M, Sethi AA, Wong PH, Os I.

Pharmacogenet Genomics. 2010 Feb;20(2):77-85. doi: 10.1097/FPC.0b013e328333f70b.

PMID:
20065889
47.

Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.

Toda T, Eliasson E, Ask B, Inotsume N, Rane A.

Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32. doi: 10.1111/j.1742-7843.2009.00453.x. Epub 2009 Aug 6.

48.

Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C9*3*3.

Bäckström T, Barkman G, Lindh JD, Eliasson E.

Eur J Clin Pharmacol. 2009 Oct;65(10):1055. doi: 10.1007/s00228-009-0670-3. Epub 2009 May 30. No abstract available.

PMID:
19484231
49.

Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.

Mannheimer B, von Bahr C, Pettersson H, Eliasson E.

Ther Drug Monit. 2008 Oct;30(5):565-9. doi: 10.1097/FTD.0b013e31818679c9.

PMID:
18728628
50.

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.

Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin RM, Pedersen RS, Sim SC, Bertilsson L, Ingelman-Sundberg M, Eliasson E.

Eur J Clin Pharmacol. 2008 Dec;64(12):1175-9. doi: 10.1007/s00228-008-0529-z. Epub 2008 Jul 25.

PMID:
18654768

Supplemental Content

Loading ...
Support Center